Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) announced on May 1, 2026 the grant of inducement stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan.

The company granted options to 17 non-executive employees for an aggregate of 731,000 shares, at a per‑share exercise price of $1.52 (closing price on the grant date). Each option vests over four years (25% after one year, then monthly) and has a 10‑year term, subject to the plan and continued service.

Positive

• 731,000 options granted (May 1, 2026)
• Grants align with Nasdaq Rule 5635(c)(4) and company plan
• Standard four‑year vesting with 25% one‑year cliff

Negative

• Options create potential for share count increase of 731,000
• Exercise price equals recent closing price ($1.52) so no immediate cash inflow

News Market Reaction – IVVD

-5.44%

9 alerts

-5.44% Session close to close

+10.4% Peak in 22 hr 22 min

$435.52M Market Cap

0.5x Rel. Volume

In the May 5 session, IVVD declined 5.44%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.4% in the session following this news. A negative reaction despite the largely ro...

Analysis

The stock moved -5.4% in the session following this news. A negative reaction despite the largely routine nature of these inducement grants would fit a pattern where secondary or administrative updates draw outsized selling in a stock already trading below its 200-day MA. The announcement covers 731,000 options at a $1.52 exercise price with standard four-year vesting. Given prior capital raises and existing registration capacity, some holders may interpret ongoing equity awards as incremental dilution risk, even without an immediate financing event.

Key Figures

Current share price: $1.47 Inducement options granted: 731,000 options Exercise price: $1.52 per share +5 more

8 metrics

Current share price $1.47 Pre-news close, IVVD common stock

Inducement options granted 731,000 options Aggregate options to 17 new non-executive employees on May 1, 2026

Exercise price $1.52 per share Inducement options, equal to May 1, 2026 closing price

Vesting schedule 4 years (25% after 1 year) Inducement options under 2026 Inducement Plan

Option term 10 years Term of inducement options granted May 1, 2026

2025 net product revenue $53.4M Full-year 2025, driven by PEMGARDA sales

Prior-year net product revenue $25.4M Full-year comparison figure from earlier period

Year-end 2025 cash $226.7M Cash and equivalents at 2025 year-end

Historical Context

5 past events · Latest: Apr 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Conference participation	Neutral	-3.5%	Chairman speaking at POLITICO Health Care Summit on viral disease prevention.
Apr 09	Pipeline progress	Positive	+31.9%	Phase 3 DECLARATION trial upsized and measles mAb VMS063 advanced toward IND.
Apr 07	Education campaign	Neutral	-0.8%	Launch of “Antibodies for Any Body” immune health education campaign with Lindsey Vonn.
Apr 06	Inducement grants	Neutral	+1.6%	Inducement stock options to 16 new hires under 2026 Inducement Plan and Nasdaq rules.
Mar 30	Scientific presentation	Positive	+9.2%	CSO presentation on mAb therapies and Invivyd’s platform at World Vaccine Congress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent IVVD news has often produced aligned price reactions, with positive clinical and presentation updates seeing upside and neutral corporate or HR items having modest impact. A prior inducement grant announcement in early April 2026 coincided with a small positive move, suggesting these HR-related updates have not historically driven large dislocations.

Recent Company History

Over the last few months, Invivyd has balanced corporate visibility, pipeline advancement, and routine HR-related grants. In March–April 2026 it highlighted scientific talks at the World Vaccine Congress and a POLITICO Health Care Summit, and advanced its measles mAb candidate VMS063 with promising in vitro data, which drew a strong +31.85% reaction on April 9. By contrast, educational campaigns and inducement option grants, including a similar grant disclosure on April 6, have generated only modest share price moves.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.52, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd  

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com 

Investor Relations
(781) 208-1747
investors@invivyd.com 

FAQ

What did Invivyd (IVVD) announce on May 5, 2026 about inducement grants?

Invivyd announced it granted inducement stock options to new hires on May 1, 2026. According to the company, 17 non‑executive employees received options totaling 731,000 shares under the 2026 Inducement Plan, subject to Nasdaq Listing Rule 5635(c)(4).

How many shares and employees were involved in Invivyd's IVVD inducement grants?

The company granted options covering 731,000 shares to 17 employees. According to the company, the grants were made as material inducements for each employee’s entry into employment on May 1, 2026.

What is the exercise price and term of the Invivyd (IVVD) inducement options?

Each option has an exercise price of $1.52 and a 10‑year term. According to the company, $1.52 represented the closing price of Invivyd common stock on the grant date.

What is the vesting schedule for the IVVD inducement option grants?

Options vest over four years with a 25% one‑year cliff, then monthly thereafter. According to the company, vesting is subject to each employee’s continuous service with Invivyd.

Do Invivyd's (IVVD) inducement grants affect shareholder dilution immediately?

The grants create potential future share issuance of 731,000 shares but do not immediately increase shares outstanding. According to the company, options must be exercised and vesting or other conditions met before shares are issued.